Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (15105)	2/14/1998 7:36:00 PM
From: squetch	Read Replies (2) \| Respond to of 32384

Financially, Henry, LGND controls all the rights to Targretin in cancer indications, correct? I stated I was skeptical of the off label usage of Targretin. I am much less so today. I would like to see the human trial data for Tamoxifen. IMO, this paper increases the off-label usage of Targretin. I think you are likely to see usage in combo w/ Tamox first. Nobody appears to be saying Targretin is unsafe in combo or monotherapy. As doctors become more comfortable w/ Targretin safety and effectiveness, you may see some higher dose monotherapy. Strong PII human data will increase the off label monotherapy use. A possible fourth usage area is in high risk women at a low dosage as a preventitive.